Molecular and cellular mechanisms of thymosin β4-mediated cardioprotection

Annals of the New York Academy of Sciences

Volumn 1269, Issue 1, 2012, Pages 102-109

  Hinkel, Rabea ^a   Trenkwalder, Teresa ^a   Kupatt, Christian ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Munich Heart Alliance   (Germany)

Author keywords

Angiogenesis; Cardioprotection; Inflammation; Ischemia reperfusion injury; Thymosin 4

Indexed keywords

THYMOSIN BETA4; TRANSCRIPTION FACTOR RELA;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEART DEVELOPMENT; HEART PROTECTION; HUMAN; INFLAMMATION; MUSCLE CELL; NONHUMAN; VASCULARIZATION;

EID: 84867391757     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06693.x     Document Type: Article

References (54)

1. Lloyd-Jones, D., R.J. Adams, T.M. Brown, et al 2010. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e246-e215.
2. Suero, J.A., S.P. Marso, P.G. Jones, et al 2001. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J. Am. Coll. Cardiol. 38: 409-414.
3. White, H.D. & D.P. Chew 2008. Acute myocardial infarction. Lancet 372: 570-584.
4. Yellon, D.M. & G.F. Baxter 1999. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc. Med. 9: 245-249.
5. Yellon, D.M. & D.J. Hausenloy 2007. Myocardial reperfusion injury. N. Engl. J. Med. 357: 1121-1135.
6. Elsasser, A., E. Decker, S. Kostin, et al 2000. A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium. Mol. Cell Biochem. 213: 17-28.
7. Gomez-Marquez, J., A.F. Franco del, P. Carpintero & R. Anadon 1996. High levels of mouse thymosin beta4 mRNA in differentiating P19 embryonic cells and during development of cardiovascular tissues. Biochim. Biophys. Acta 1306: 187-193.
8. Hatzopoulos, A.K., J. Folkman, E. Vasile, et al 1998. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development 125: 1457-1468.
9. Kupatt, C., J. Horstkotte, G.A. Vlastos, et al 2005. Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia. FASEB J. 19: 1576-1578.
10. Bock-Marquette, I., A. Saxena, M.D. White, et al 2004. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432: 466-472.
11. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6: 389-395.
12. Smart, N., C.A. Risebro, A.A.D. Melville, et al 2007. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445: 177-182.
13. Banerjee, I., J. Zhang, T. Moore-Morris, et al 2012. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ. Res. 110: 456-464.
14. Smart, N., C.A. Risebro, A.A. Melville, et al 2007. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Ann. N.Y. Acad. Sci. 1112: 171-188.
15. Tevosian, S.G., A.E. Deconinck, et al 2000. FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell 101: 729-739.
16. Giordano, F.J., H.P. Gerber, S.P. Williams, et al 2001. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl. Acad. Sci. USA 98: 5780-5785.
17. Bock-Marquette, I., S. Shrivastava, G.C. Pipes, et al 2009. Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. J. Mol. Cell Cardiol. 46: 728-738.
18. Grant, D.S., J.L. Kinsella, M.C. Kibbey, et al 1995. Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. J. Cell Sci. 108: 3685-3694.
19. Koutrafouri, V., L. Leondiadis, K. Avgoustakis, et al 2001. Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim. Biophys. Acta. 1568: 60-66.
20. Koutrafouri, V., L. Leondiadis, N. Ferderigos, et al 2003. Synthesis and angiogenetic activity in the chick chorioallantoic membrane model of thymosin beta-15. Peptides 24: 107-115.
21. Lee, S.H., M.J. Son, S.H. Oh, et al 2005. Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res. 65: 137-148.
22. Mu, H., R. Ohashi, H. Yang, et al 2006. Thymosin beta10 inhibits cell migration and capillary-like tube formation of human coronary artery endothelial cells. Cell Motil. Cytoskeleton 63: 222-230.
23. Malinda, K.M., A.L. Goldstein & H.K. Kleinman 1997. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 11: 474-481.
24. Grant, D.S., W. Rose, C. Yaen, et al 1999. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis 3: 125-135.
25. Philp, D., T. Huff, Y.S. Gho, et al 2003. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 17: 2103-2105.
26. Huff, T., C.S. Muller, A.M. Otto, et al 2001. Beta-thymosins, small acidic peptides with multiple functions. Int. J. Biochem. Cell Biol. 33: 205-220.
27. Smart, N., A. Rossdeutsch & P.R. Riley 2007. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis 10: 229-241.
28. Jo, J.O., S.R. Kim, M.K. Bae, et al 2010. Thymosin beta4 induces the expression of vascular endothelial growth factor (VEGF) in a hypoxia-inducible factor (HIF)-1alpha-dependent manner. Biochim. Biophys. Acta 1803: 1244-1251.
29. Freeman, K.W., B.R. Bowman & B.R. Zetter 2011. Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB J. 25: 907-915.
30. Qiu, F.Y., X.X. Song, H. Zheng, et al 2009. Thymosin beta4 induces endothelial progenitor cell migration via PI3K/Akt/eNOS signal transduction pathway. J. Cardiovasc. Pharmacol. 53: 209-214.
31. Asahara, T., T. Murohara, A. Sullivan, et al 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967.
32. Hinkel, R., I. Bock-Marquette, A.K. Hatzopoulos & C. Kupatt 2010. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann. N.Y. Acad. Sci. 1194: 105-111.
33. Bicer, A., O. Karakurt, R. Akdemir, et al 2011. Thymosin beta 4 is associated with collateral development in coronary artery disease. Scand. J. Clin. Lab Invest. 71: 625-630.
34. Lv, S., G. Cheng, Y. Xu, et al 2011. Relationship between serum thymosin beta4 levels and coronary collateral development. Coron. Artery Dis. 22: 401-404.
35. Vinten-Johansen, J. 2004. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc. Res. 61: 481-497.
36. van, R.N., I. Hoefer, I. Buschmann, et al 2003. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovasc. Res. 57: 178-185.
37. Sosne, G., C.C. Chan, K. Thai, et al 2001. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp. Eye Res. 72: 605-608.
38. Sosne, G., E.A. Szliter, R. Barrett, et al 2002. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp. Eye Res. 74: 293-299.
39. Sosne, G., P. Qiu, P.L. Christopherson & M.K. Wheater 2007. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp. Eye Res. 84: 663-669.
40. Qiu, P., M.K. Wheater, Y. Qiu & G. Sosne 2011. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 25: 1815-1826.
41. Babakov, V.N., O.A. Petukhova, L.V. Turoverova, et al 2008. RelA/NF-kappaB transcription factor associates with alpha-actinin-4. Exp. Cell Res 314: 1030-1038.
42. Young, J.D., A.J. Lawrence, A.G. MacLean, et al 1999. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat. Med. 5: 1424-1427.
43. Lee, J.T. 1992. Antibiotic prophylaxis and surgical-wound infections. N. Engl. J. Med. 327: 205.
44. Badamchian, M., M.O. Fagarasan, R.L. Danner, et al 2003. Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int. Immunopharmacol. 3: 1225-1233.
45. Huff, T., A.M. Otto, C.S. Muller, et al 2002. Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J. 16: 691-696.
46. Mannherz, H.G. & E. Hannappel 2009. The beta-thymosins: intracellular and extracellular activities of a versatile actin binding protein family. Cell Motil. Cytoskeleton 66: 839-851.
47. Hinkel, R., C. El-Aouni, T. Olson, et al 2008. Thymosin beta 4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation 117: 2232-2240.
48. Smart, N., S. Bollini, K.N. Dube, et al 2011. De novo cardiomyocytes from within the activated adult heart after injury. Nature 474: 640-644.
49. Zhou, B., L.B. Honor, Q. Ma, et al 2012. Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J. Mol. Cell Cardiol. 52: 43-47.
50. Kispert, A. 2012. No muscle for a damaged heart: thymosin beta 4 treatment after myocardial infarction does not induce myocardial differentiation of epicardial cells. J. Mol. Cell Cardiol. 52: 10-12.
51. Kumar, S. & S. Gupta 2011. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One 6: e26912.
52. Sopko, N., Y. Qin, A. Finan, et al 2011. Significance of thymosin beta4 and implication of PINCH-1-ILK-alpha-parvin (PIP) complex in human dilated cardiomyopathy. PLoS One 6: e20184.
53. Ruff, D., D. Crockford, G. Girardi & Y. Zhang 2010. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann. N.Y. Acad. Sci. 1194: 223-229.
54. Dube, K.N., S. Bollini, N. Smart & P.R. Riley 2012. Thymosin beta4 protein therapy for cardiac repair. Curr. Pharm. Des 18: 799-806.